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Research Article
TREM2 shedding by cleavage at the H157-S158 bond
is accelerated for the Alzheimer’s disease-associated
H157Y variant
Peter Thornton1,†, Jean Sevalle2,†, Michael J Deery3,#, Graham Fraser1, Ye Zhou2, Sara Ståhl4,
Elske H Franssen1, Roger B Dodd5,6, Seema Qamar5, Beatriz Gomez Perez-Nievas1, Louise SC Nicol6,
Susanna Eketjäll7, Jefferson Revell6, Clare Jones6, Andrew Billinton1, Peter H St George-Hyslop2,5,‡,
Iain Chessell1,‡ & Damian C Crowther1,‡,*
Abstract
We have characterised the proteolytic cleavage events responsible
for the shedding of triggering receptor expressed on myeloid cells
2 (TREM2) from primary cultures of human macrophages, murine
microglia and TREM2-expressing human embryonic kidney
(HEK293) cells. In all cell types, a soluble 17 kDa N-terminal cleav-
age fragment was shed into the conditioned media in a constitu-
tive process that is inhibited by G1254023X and metalloprotease
inhibitors and siRNA targeting ADAM10. Inhibitors of serine
proteases and matrix metalloproteinases 2/9, and ADAM17 siRNA
did not block TREM2 shedding. Peptidomimetic protease inhibitors
highlighted a possible cleavage site, and mass spectrometry con-
firmed that shedding occurred predominantly at the H157-S158
peptide bond for both wild-type and H157Y human TREM2 and for
the wild-type murine orthologue. Crucially, we also show that the
Alzheimer’s disease-associated H157Y TREM2 variant was shed more
rapidly than wild type from HEK293 cells, possibly by a novel,
batimastat- and ADAM10-siRNA-independent, sheddase activity. These
insights offer new therapeutic targets for modulating the innate
immune response in Alzheimer’s and other neurological diseases.
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Introduction
Nasu–Hakola disease is a rare but fatal brain and bone disorder
(Hakola, 1972; Hakola & Iivanainen, 1973), caused by homozygous
inheritance of null or hypomorphic variants of the TREM2 gene
(Klu¨nemann et al, 2005). A subset of heterozygous TREM2 variants
such as R47H, R62H and H157Y are associated with increased risk
of Alzheimer’s disease (AD) (Guerreiro et al, 2013; Jonsson &
Stefansson, 2013; Jonsson et al, 2013; Slattery et al, 2014; Finelli et al,
2015; Ghani et al, 2016; Jiang et al, 2016). While the prevalence of
AD-linked TREM2 variants is low, indeed the most common (R47H)
affects 0.3–0.6% of the population (Guerreiro et al, 2013; Jonsson
et al, 2013), the relative risk for individual carriers is high, twofold to
11-fold above the general population (Finelli et al, 2015).
TREM2 is a single-pass, type I transmembrane protein that
includes an extracellular immunoglobulin domain with two N-
linked glycans (Park et al, 2015). It is expressed on dendritic cells,
macrophages, microglia and osteoclasts and is thought to act as a
scavenger receptor (Colonna, 2003). TREM2 is prominent in micro-
glia adjacent to pathological material such as amyloid deposits and
cellular debris and may have a role in directing microglial migration
(Jay et al, 2015; Kawabori et al, 2015) and phagocytic activation
(Keren-Shaul et al, 2017). Studies in cell cultures have shown that
at least Nasu–Hakola-linked TREM2 variants are less available on
the surface of phagocytic cells because they are incorrectly
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glycosylated (Kleinberger et al, 2014; Park et al, 2015) and ineffi-
ciently trafficked through the synthetic pathway. Most individuals
with AD carry wild-type TREM2 and the normal proteolytic process-
ing of the protein is thought to be performed by sequential a- then
c-secretase activity (Wunderlich et al, 2013). It is notable that levels
of the shed TREM2 N-terminal fragment (NTF) are raised in the CSF
of patients with sporadic AD as compared to healthy controls
(Heslegrave et al, 2016; Piccio et al, 2016; Sua´rez-Calvet et al,
2016b).
In this study, we have investigated the properties of the
protease (the sheddase) that results in shedding of TREM2 from
the surface of primary human and murine myeloid cells. We find
that the sheddase activity is sensitive to metalloprotease inhibitors
and cleaves at the H157-S158 peptide bond, in both primary
human macrophages and mouse microglia. We investigate the
effect of the disease-associated H157Y substitution and show that
it may recruit a novel sheddase, possibly explaining its pathogenic
mechanism.
Results
TREM2 is expressed on the surface of human cells and the
N-terminal fragment is shed into the conditioned medium
Non-permeabilised primary human macrophages showed high
levels of TREM2 expression on their cell surfaces when probed
with the AF1828 polyclonal antibody (Fig 1A, 1, red) but not with
control goat serum (Fig 1A, 2). Likewise, stable-expressing
hTREM2-HEK293 cells showed TREM2 on their surface (Fig 1A, 3,
pink), which was not seen in the untransfected parental cells
(Fig 1A, 4). In both cell types, Western blots of the cell lysates
and conditioned media showed a range of TREM2 isoforms
(Fig 1B). The lysates (L) contained a predominant 35 kDa band
with a less intense smear up to 50 kDa. By contrast, this higher
molecular weight smear is the major TREM2 species in the culture
supernatants (S) from both HEK293 + hTREM2 and human
primary macrophages.
We investigated the kinetics of TREM2 metabolism in primary
human macrophages by biotin pulse labelling of surface-exposed
protein and then following the fate of biotin-conjugated TREM2 in
various subcellular fractions over time (Fig 1C, raw data Fig EV1).
It is notable that the surface-exposed TREM2 has a short half-life
of < 1 h and that the bulk of the lost protein appears in the
supernatant. Very little surface-expressed TREM2 was seen to
internalise into cytoplasmic or nuclear compartments under basal
conditions.
A
B
C
Figure 1. TREM2 expression, glycosylation and proteolysis.
A Surface TREM2 was detected on non-permeabilised primary human
macrophages labelled with anti-TREM2 polyclonal antiserum (1, red), but
not a control antiserum (2) and by live cell immunostaining of HEK293
stably transfected with wild-type hTREM2 (3, pink; nuclei stained with
Hoechst) but not on parental HEK293 (4). Surface immunolocalisation was
also observed. Scale bars = 20 lm.
B Western blots of lysates (L) and supernatants (S) for hTREM2 from parental
HEK293 vs. HEK293+hTREM2 cells showed distinct isoforms of TREM2. The
cell lysate (HEK293+hTREM2, L) yielded an immature glycoform at 35 kDa
with a less intense smear up to 50 kDa. This smear was the predominant
species in the supernatant (HEK293+hTREM2, S). Similar distributions of
TREM2 were seen in primary human macrophages (Macrophage, L and S).
C Subcellular fractionation of macrophages over a time course revealed the
fate of surface-biotinylated TREM2 (membrane-associated in blue circles),
indicating that most protein was shed into the supernatant (red squares),
with a half time of < 1 h, and that little was found in cytosol or nuclear
cellular fractions (green triangles & purple inverted triangles). Data plotted
as mean  SEM; n = 4 replicates.
Source data are available online for this figure.
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Proteolytic release of a 17 kDa TREM2 N-terminal fragment into
the supernatants of primary mouse microglia, primary human
macrophages and HEK293 cells
Soluble TREM2 NTF was detected by Western blotting the condi-
tioned medium from primary murine microglia and primary human
macrophages; a similar result was also seen for HEK293 cells (Fig 2A).
The high molecular mass smear of immunoreactivity (> 35 kDa) was
likely due to extensive and variable glycosylation of the NTF because
only a single band of 17 kDa was observed following deglycosylation.
In primary human macrophages, and in wild-type hTREM2-expressing
HEK293 cells, the ADAM10-specific metalloprotease inhibitor
GI254023X reduced shedding. The potencies of GI254023X and a
broad-spectrum metalloprotease inhibitor (GM6001) were quantified
by a Meso Scale Discovery (MSD) assay for shed TREM2 and were
shown to be similar in macrophages (Fig 2B), inhibiting shedding by
~50% at 20 lM. Under the same conditions, the broad-spectrum
serine protease inhibitor PMSF did not inhibit TREM2 shedding at
concentrations exceeding 100 lM (Fig 2B). GI254023X and GM6001
also inhibited shedding in HEK293 cells; additionally, the MMP2/9
inhibitor SB-3CT failed to inhibit shedding (Fig 2C).
Peptidomimetic protease inhibitors point to residues 158–160 as
the site of sheddase cleavage
We synthesised a tiled library of reverse-sequence D-amino acid
(retro-inverso) polypeptides that replicated both the biophysical
characteristics and the specific side-chain interactions of peptides
constituting the peri-membrane region of TREM2 (Li et al, 2010)
(Fig 3A). Unlike natural L-amino acid polypeptides, these
A
B C
Figure 2. Shedding of glycosylated TREM2 NTF is sensitive to inhibitors of ADAM10 and matrix metalloproteinases.
A Western blotting of the conditioned media from primary murine microglia (left panel), transfected HEK293 cells (middle panel) and primary human macrophages
(right panel) revealed the presence of shed wild-type TREM2. This soluble TREM2 appeared as a > 35 kDa smear of various glycoforms and upon deglycosylation was
reduced to a single band of 17 kDa (arrowhead). The ADAM10 inhibitor, GI254023X, blocked shedding in transfected HEK293 cell and macrophage cultures.
B The concentration of shed TREM2 in the supernatant of macrophage cultures was reduced to ~50% by 20 lM of both GI254023X and the broad-spectrum
metalloprotease inhibitor GM6001, as measured by an MSD assay. By contrast, the broad-spectrum serine protease inhibitor PMSF did not reduce shedding.
Experiments were repeated three times and for two donors of the macrophage progenitors. Data plotted as mean ± SEM.
C In HEK293 cells, GI254023X and GM6001 had comparable potencies; however, the MMP2/9 inhibitor SB-3CT did not block shedding. Data plotted as mean  SEM;
n = 3 replicates.
Source data are available online for this figure.
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peptidomimetics are resistant to proteolysis (Taylor et al, 2010) and
at millimolar concentrations predictably act as competitive protease
inhibitors. The levels of TREM2 NTF in the conditioned media of
macrophage cultures treated with the peptidomimetics were
compared with the levels in the media of untreated cultures. We
found that all retro-inverso peptides that included residues 158–160
(C’-fedahvehsis-N’, C’-hvehsisrsll-N’, C’-hvehsis-N’ & C’-sisrsll-N’)
inhibited shedding, whereas other members of the library (C’-sllegei-N’,
C’-geipfpp-N’ & C’-fpptsil-N’), analogous to nearby peri-membrane
regions of TREM2, did not (Fig 3B and C).
To understand whether the protease inhibition was strictly
sequence specific, we synthesised a D-polypeptide with the reverse
sequence of the most effective inhibitor (C’-hvehsisrsll-N’). This
reverse retro-inverso peptide was equally effective at preventing
TREM2 shedding (Fig 3D), indicating that access to the protease is
determined less by the specific amino acid sequence as by general
biophysical characteristics such as charge.
Mass spectrometry identifies His157-Ser158 as the main sheddase
cleavage site in wild-type and disease-linked variants of TREM2
Immunoprecipitation, using a goat polyclonal anti-hTREM2
(AF1828, R&D Systems) from the conditioned medium of primary
human macrophages, followed by deglycosylation, yielded two
specific bands on a silver-stained protein gel (Fig 4A, single
biological replicate run in duplicate lanes). The upper band had a
molecular mass of 17 kDa, consistent with the expected size of the
NTF (arrowhead 1); running slightly ahead of this was a 15 kDa
protein (arrowhead 2). SDS–PAGE purification and trypsin digestion
of these bands yielded peptides that were analysed by LC-MS/MS,
using the published TREM2 sequence as the search guide (PubMed
references: human: NP_061838.1 & mouse: NP_001259007.1). Similar
mass spectrometric assays were performed independently and in
duplicate for the conditioned media of primary human macro-
phages, primary murine microglia and HEK293 cells stably express-
ing hTREM2. Murine TREM2 was immunoprecipitated with a rat
anti-mTREM2 monoclonal (MAB1729, R&D Systems). The condi-
tioned media were derived from two donors (macrophages and
microglia) or from two independent cultures of HEK293 cells. Those
peptides with C-terminal Arg and Lys residues were considered to
result from trypsin cleavage while peptides with other C-terminal
residues were likely the result of sheddase activity. For experiments
that yielded non-trypsin-derived peptide fragments, we plotted their
frequency against the peri-membrane sequence of TREM2 (Fig 4B).
Mass spectrometry yielded almost complete coverage of the
extracellular domain of TREM2 (Fig 4C). For the 17 kDa band 1
A
B C D
Figure 3. Peptidomimetic protease inhibitors point to residues 158–160 as the site of sheddase cleavage.
A An overlapping library of retro-inverso peptides were designed to mimic the extracellular peri-membranous domain of TREM2 in the region of the sheddase site
(TM: transmembrane). Blue boxes represent retro-inverso peptides that reduce TREM2 shedding; red boxes those that do not. The black box indicates the three
residues that are common to all the inhibitory retro-inverso peptides.
B The peptidomimetics were incubated with primary human macrophages, and the resulting levels of shed TREM2 NTF were quantified by MSD ELISA. Blue =
inhibitory; red = non-inhibitory. Values plotted: mean  SEM; each experiment was repeated for 3–5 independent human donors.
C Peptides including amino acids 158–160 (blue) inhibited TREM2 shedding more than retro-inverso peptides that did not (red). Values plotted: mean  SEM;
two-tailed Student’s t-test, ***P = 0.003; each experiment was repeated for 3–5 independent human donors.
D Forward and reverse TREM2 peptidomimetics containing residues 158–160 suppressed TREM2 shedding equally. Values plotted: mean  SEM; n = 3 replicates;
two-tailed Student’s t-test; ns = not significant.
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D
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B
Figure 4. Mass spectrometry identifies His157-Ser158 as the sheddase site.
A TREM2 was immunoprecipitated and deglycosylated from primary human macrophage conditioned media. Two specific bands were visible on a silver-stained
SDS–PAGE gel (arrowheads 1 & 2). These bands were excised, digested with trypsin and analysed by LC-MS/MS.
B TREM2 in the conditioned media of primary human macrophages (black), primary murine microglia (white) and HEK293 cells stably expressing hTREM2 (grey) was
digested with trypsin and the resulting peptides identified by mass spectrometry. The most frequent C-terminal residue not consistent with trypsin digestion was
H157 (from two donors/biological replicates of HEK293 cells; each replicate assayed in separate mass spectrometry laboratories; n = total number of peptides
identified; where peptide sequences differ between species they are shown as human/mouse).
C Trypsin digestion (red sites) of band 1 provided almost complete coverage of macrophage TREM2 (bold), lacking only the peptide expected to have R52 at its
C-terminus. Non-trypsin cleavage (blue) was observed predominantly at H157. The absence of the peptide with K42 at its C-terminus suggests that N-terminal
truncation is responsible for generating band 2. Underlined: predicted secretion signal peptide.
D Peptides from the supernatants of HEK293 cells transiently expressing wild-type (black) and H157Y (white) human TREM2, and co-expressing human DAP12, were
identified by mass spectrometry. The most common C-terminus was residue 157 for both TREM2 isoforms (one biological replicate; n = total number of peptides
identified; where WT and variant sequences vary they are shown as WT/variant).
E Schematic of the TREM2 protein. SP, signal peptide; IG domain, immunoglobulin domain; TM, transmembrane domain; triangles, N-glycosylation sites; arrow, site of
proteolytic shedding; all numbers relate to amino acid positions.
Source data are available online for this figure.
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from primary human macrophages, we observed peptides that
included the N-terminus through to the most distal non-trypsin
cleavage sites. These cleavages, likely due to the sheddase,
occurred most commonly at H157, with such peptides accounting
for up to 10% of all TREM2 peptides detected. Other nearby non-
trypsin sites at positions 158 and 159 each accounted for < 0.1%
of the peptides observed. Across all three cell types, H157 was
the most common site with other non-trypsin sites each account-
ing for < 1% of the total peptides observed. The 15 kDa band 2,
from primary human macrophages, yielded similar peptide frag-
ments but lacked the most N-terminal sequence, making it likely
that a second endoproteolytic event within the first 34 amino
acids of TREM2 is a common occurrence. Control experiments in
which cell-free, full-length, recombinant TREM2 was digested
with trypsin did not yield peptides with H157 at the C-terminus,
instead the expected tryptic peptides ending with R161 were
observed (data not shown).
In the same way, we identified peptides in the conditioned
medium of HEK293 cell lines transiently expressing wild-type (Fig
4D, black) and H157Y (white) human TREM2 and co-expressing
human DAP12. For both isoforms, residue 157 was the predominant
C-terminal residue indicating that the site of proteolysis is largely
unaffected by the substitution of a non-polar tyrosine for the polar
histidine at the P1 position (see Fig 4E for schematic of cleavage site).
The H157Y substitution accelerates TREM2 shedding from
HEK293 cells
The H157Y variant of TREM2 carries an increased risk of AD
(Jiang et al, 2016) although, like the R47H variant, the mecha-
nism is unknown. To test whether H157Y substitution alters the
proteolytic metabolism of TREM2, we expressed the wild-type and
the variant proteins in HEK293 cells. Levels of cell-associated
TREM2 in cell lysates (Fig 5A) and shed TREM2 in conditioned
media (Fig 5C) TREM2 were measured by Western blot (full-
length TREM2 species quantified in Fig 5B and cleaved fragments
in Fig 5D). Both wild-type and H157Y variant TREM2 expressed
at similar levels. However, for H157Y TREM2 there was a
reduction in mature glycoforms in the cell lysates, whereas the
immature glycoforms were equivalent (blot in Fig 5A, quantified
in Fig 5B). This altered ratio is unlikely the result of impaired
delivery of the variant to the cell surface because levels of both
the TREM2 C-terminal fragment (CTF, blot in Fig 5A, quantified
in Fig 5D) and NTF (blot in Fig 5C, quantified in Fig 5D) are
higher for the H157Y variant as compared to wild type. Rather it
appears that mature H157Y TREM2 is shed more rapidly from the
cell surface.
We then treated the HEK293 cells expressing TREM2 with
protease inhibitors GI254023X and batimastat. Remarkably, while
GI254023X inhibited the shedding of wild-type and H157Y variant
TREM2 equally (Fig 5E), by contrast batimastat was only partially
effective in preventing the shedding of H157Y variant TREM2
(Fig 5F; batimastat titration in Fig EV2; Fig 5G: schematic of
expected protease activities). This may indicate that the H157Y vari-
ant is susceptible to a novel proteolytic activity. We repeated these
assays of TREM2 proteolysis in HEK293 cells expressing the equiva-
lent halotagged constructs with essentially identical results
(Fig EV3).
Knock-down of ADAM10 is particularly effective at reducing the
shedding of wild-type TREM2
HEK293 cells expressing either WT or H157Y TREM2 were
treated with pooled siRNA constructs (Dharmacon) targeting
either ADAM10 and/or ADAM17 (Fig 6A and B). After incubat-
ing the treated cells for 72 h, the concentration of TREM2 NTF
in the conditioned media was measured by MSD assay.
ADAM10, but not ADAM17, knock-down reduced the shedding
of TREM2 NTF for both WT and the H157Y variant. Control
experiments indicated that the levels of TREM2 in the cell pellet
were unchanged by siRNA treatment (N = 2, data not shown).
The blockade of TREM2 shedding, as measured by reduction in
the levels of the NTF in the conditioned medium following
ADAM10 siRNA, was greater for the WT protein (45.0%) as
compared to the variant (30.0%, N = 8, P = 104, one-tailed
Student’s t-test, Fig 6C). This result further supports the involve-
ment of proteases other than ADAM10, but not ADAM17, in the
shedding of the H157Y variant.
▸Figure 5. The disease-linked H157Y variant of TREM2 is shed more rapidly than wild-type TREM2.A Western blot for TREM2 in lysates of HEK293 cells transiently expressing either wild-type (WT) or the H157Y variant protein (N = 3): levels of immature TREM2 (major
band at 35 kDa) were unchanged by the H157Y substitution; however, total levels of the variant were reduced as compared to WT because of a more marked
reduction in the levels of the glycosylated isoform. The proteolytic cleavage of TREM2 generated a truncated C-terminal fragment (CTF) that was more abundant in
lysates from cells expressing H157Y TREM2. GAPDH was the loading control; DAP12 was co-expressed with TREM2. Molecular mass markers in kDa.
B Quantitation of the full-length TREM2 isoforms as shown in panel (A) (data plotted as mean  SEM; N = 12).
C Western blot for the shed TREM2 NTF from the conditioned medium of HEK293 cell cultures (N = 3): levels of H157Y TREM2 NTF were higher than WT. A secreted
fragment of the amyloid precursor protein (sAPPa) was the loading control. Molecular mass markers in kDa.
D The proteolytic fragments of TREM2 as shown in panel (A) (CTF, N = 3) and panel (C) (NTF, N = 15) were corrected for the total full-length TREM2 (FL) from each cell
lysate: the levels of the shed N-terminal fragment (NTF) of TREM2 were higher in cells expressing the H157Y variant as compared to WT. Data plotted as mean 
SEM.
E Western blot for TREM2 from the conditioned medium of HEK293 cell cultures treated with varying concentrations of either GI254023X or batimastat (bat): inhibition
of TREM2 NTF shedding by GI254023X was equivalent for both variant and WT TREM2; however, more shedding was observed at the higher concentration of
batimastat for H157Y TREM2 as compared to WT. Molecular mass markers in kDa.
F Quantification of total TREM2 shed from HEK293 cells as shown in panel (E) (N = 7). Maximal concentrations of GI254023X blocked shedding equally for WT and
variant TREM2. Batimastat-resistant shedding was more marked for H157Y TREM2. Data plotted as mean  SEM.
G Schematic showing the proteolytic enzymes expected to be active in the presence of the protease inhibitors used in (E and F). MMP: matrix metalloproteinase.
Data information: Concentration of inhibitors in micromolar. Two-tailed Student’s t-test, P-values: *P < 0.05; ***P < 0.001.
Source data are available online for this figure.
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Discussion
The role of neuroinflammation in neurodegenerative diseases is the
focus of intense research effort, not least because of the genetic
evidence pointing to the importance of the innate immune system in
AD. Variants of TREM2 that are linked with Nasu–Hakola disease
and/or AD appear to show loss of function phenotypes, perhaps
rendering microglia less able to remove inflammatory material from
the brain. While there is experimental support for TREM2 playing
such a protective role during amyloid plaque deposition (Wang
et al, 2015; Yuan et al, 2016), there are also conflicting accounts
(Jay et al, 2015). The apparent experimental discordance is likely
due to different age-related effects on plaque deposition in TREM2
knock-out mouse models (Jay et al, 2017). In addition to its role in
phagocytosis, TREM2 also signals through its co-receptor DAP12,
resulting in a cascade of phosphorylation mediated by ERK and Syk
amongst other kinases (Xing et al, 2015). We know this signalling
function is essential for health because mutations in DAP12 have
also been linked to Nasu–Hakola disease (Paloneva et al, 2000).
TREM2 signalling likely has anti-inflammatory consequences
(Hamerman et al, 2005, 2006; Takahashi et al, 2005) and so any
disease-linked downregulation would be expected to hamper resolu-
tion of an inflammatory reaction.
In this study, we have confirmed that the TREM2 sheddases in
primary human macrophages and in primary murine microglia
release TREM2 NTFs of a similar size into the culture supernatant.
When deglycosylated, the predominant, larger species has a molecu-
lar mass of 17 kDa, while a smaller fragment of 15 kDa is also
present. Concomitantly, the corresponding CTF accumulates in the
cell lysate fraction. Using surface biotinylation, we observed that the
turnover of TREM2 on the surface of macrophages is remarkably
rapid, having a half-life of < 1 h, with most material being shed into
the medium. Such rapid cycling predicts that a small change in either
the rates of delivery to, or shedding from, the cell surface may result
in significant changes in steady-state surface expression.
To quickly focus on the likely sheddase site, we used a tiled
library of retro-inverso peptidomimetics that were structurally simi-
lar to the extracellular peri-membranous region of TREM2. We
found mimetics that reduced shedding from HEK293 cells all
included residues analogous to amino acids 158–160 (N’-SIS-C’)
from WT TREM2. The most effective inhibitor, C’-hvehsisrsll-N’,
was then synthesised as the corresponding reverse-sequence D-poly-
peptide, ostensibly as a negative control. Predictably, this reverse
retro-inverso peptidomimetic will not conserve structure-specific
side-chain interactions; however, general biophysical characteristics
such as hydrophobicity and charge distribution will be conserved.
The finding that both the forward and reverse peptidomimetics were
equally potent at blocking shedding indicates that their activity
likely depends on the biophysical combination of negative and posi-
tive charges in the peptide. Indeed, the glutamate–arginine pairing
found in the mimetic resembles the ideal ADAM10 substrate
proposed by Caescu and colleagues (Caescu et al, 2009).
We then used mass spectrometry to show that the sheddase cleav-
age site in human and mouse TREM2 occurs N-terminal to the tripep-
tide that we had identified, namely at the H157-S158 bond. This
cleavage site is in the juxtamembrane region of the protein and is 17
amino acids from the predicted transmembrane domain. Such peri-
membrane cleavage is typical for a-secretase activity (Kleinberger
A
C
B
Figure 6. Knock-down of ADAM10 is less effective at reducing the
shedding of H157Y TREM2.
A, B Western blot of HEK293 cells for ADAM10 (A) or ADAM17 and reprobed
for b-actin (B) confirmed siRNA-mediated knock-down of target proteins
(arrowheads). siRNA pools, or vehicle, added to cells as indicated. b-actin
(asterisk) was the loading control.
C Quantitation of WT and H157Y (SEM error bars) TREM2 NTF in the
conditioned media of HEK293 cells as compared to untreated cells
measured by MSD assay (N = 8): ADAM10 siRNA reduced shedding
whether applied alone or in combination with ADAM17 siRNA. ADAM17
siRNA was ineffective. Fractional inhibition of shedding was greatest for
WT TREM2 using ADAM10 siRNA.
Source data are available online for this figure.
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et al, 2014) and, as expected, the principal sheddase responsible for
cleavage of wild-type TREM2 appears to be a metalloprotease, its
activity being substantially blocked by GM6001, GI254023X and bati-
mastat. By contrast, the sheddase was inhibited by neither the serine
protease inhibitor PMSF nor the MMP2/9 inhibitor SB-3CT.
We have shown that the H157Y substitution, which is associated
with increased risk of AD, results in accelerated cleavage and loss of
TREM2, particularly the mature glycoforms, from the surface of
HEK293 cells. Both the CTF and the shed NTF accumulate
more rapidly in HEK293 cells expressing the variant as compared to
wild-type TREM2. Mass spectrometric detection of shed peptides
indicated that residue 157 is the most common C-terminal residue
for both wild-type and H157Y TREM2. While GI254023X fully blocks
the enhanced cleavage of H157Y TREM2, by contrast batimastat is
less effective. This observation is consistent with the variant being
susceptible to cleavage by one, or more, additional proteolytic
enzymes. To investigate this further, we used siRNA to knock down
either ADAM10 or ADAM17, or both. This experiment clearly
showed that ADAM10 was the only enzyme of the two that was
acting as a sheddase; however, the ADAM10 knock-down was more
effective at preventing WT TREM2 shedding as compared to H157Y.
Further work will be needed to determine whether the differential
effects of batimastat and ADAM10 siRNA reflect structural alter-
ations induced by the H157Y substitution, making it a preferred
substrate for ADAM10. An alternative explanation is that the variant
is a substrate for a completely independent protease.
While our results provide a molecular mechanism for how the
H157Y variant might alter risk of AD, they do not presently shed
light on whether the pathogenic effect of the accelerated cleavage
could arise from more rapid removal of TREM2 from the cell surface
and/or from the increased abundance of the released NTF. Regard-
less, our observations suggest that selective partial inhibition of
cleavage of TREM2 at H157-Ser158 bond might provide a potential
therapeutic strategy for carriers of the H157Y and possibly for indi-
viduals with wild-type TREM2. More generally, the increased CSF
levels of soluble TREM2 in sporadic (Heslegrave et al, 2016; Piccio
et al, 2016; Sua´rez-Calvet et al, 2016b) and familial AD (Sua´rez-
Calvet et al, 2016a) argue that increased TREM2 NTF shedding is
important in the common sporadic form of AD as well as in rare
TREM2-dependent forms.
Materials and Methods
Macrophage cell culture
Primary human macrophages were differentiated from peripheral
blood monocytes isolated from leucocyte cones (NHSBT, UK,
samples obtained from healthy donors with informed consent
according to the WMA Declaration of Helsinki and the Department
of Health and Human Services Belmont Report) derived from male
donors. Briefly, leucocyte cones were diluted to a volume of 40 ml
in PBS and mononuclear cells isolated on polysucrose gradient. Cells
were washed in PBS and plated in Corning flasks for 1 h in serum-
free medium. Non-adherent contaminating cells were removed and
remaining monocytes differentiated for 10 days with recombinant
human GM-CSF (R&D Systems, 10 ng/ml) in RPMI with 10% v/v
foetal bovine serum (FBS) and 1% w/v penicillin–streptomycin
(Invitrogen, Sigma, UK) and incubated at 37°C, 5% v/v CO2 and
95% v/v O2.
Isolation and culture of neonatal microglia
Primary cultures of mixed murine glial cells were cultured from C57/
BL6 P2 neonatal pups, purchased post-mortem from Charles River.
Briefly, brains were extracted, rolled across sterile filter paper to
remove vasculature and meninges and were mechanically dissociated.
Cells were resuspended in 40 ml per 175 cm2 flask (Corning, UK) and
were maintained in Dulbecco’s modified Eagle’s medium (DMEM)
with 10% v/v FBS and 1% w/v penicillin–streptomycin (Invitrogen,
Sigma, UK) and incubated at 37°C (5% v/v CO2/95% v/v O2). A
week later, the media was replaced containing recombinant murine
GM-CSF (5 ng/ml, R&D systems, UK) and the cells were maintained
for a further week. One week later, microglial cells were harvested by
overnight shaking in an orbital shaker incubator (37°C, 180 rpm) and
plated at 1–1.5 × 106/ml in 175 cm2 flasks.
Transfection of hTREM2 and hDAP12 into HEK293 cells and
cleavage monitoring in HaloTag-expressing cells
Naı¨ve HEK293 cells were transiently transfected with constructs
expressing hDAP12 and hTREM2 (wild type or H157Y mutant
fused or not at the N-terminus with a HaloTag). Twenty-four or
48 h after Lipofectamine 2000-mediated transfection, the culture
medium was replaced and then conditioned for 5 h (HaloTag-
TREM2) or 24 h (untagged TREM2) before collection. For stable
expression, selection medium was added and cells grown as a
stably expressing unsorted pool. Cell supernatants and lysates,
prepared in Cell Lysis Buffer (Cell Signalling), were collected from
cultures and stored at 80°C prior to analysis. Shed HaloTag-NTF
and surface-exposed HaloTag-TREM2 were detected (Fig EV3) by
including non-cell-permeant HaloTag ligand Alexa Fluor 660
(Promega) in the culture medium. Supernatants were subjected to
SDS–PAGE, and proteins from the cell lysates were processed as
described below.
Immunocytochemistry
Cells were blocked in HBSS (Gibco), 20 mM HEPES (Gibco),
10% v/v donkey serum (Abcam) (20 lg/ml Fc fragment was added
for human macrophages, Rockland). Cells received primary antibod-
ies (AF1828, goat anti-hTREM2 N-terminal domain, from R + D
Systems, 2 lg/ml), spiked into the above block buffer for 1 h on
ice. Control experiments used naı¨ve goat serum as the primary anti-
body. Cells were rinsed twice with ice-cold HBSS and received
donkey anti-goat Alexa Fluor 546 or 647 (Life Technologies) at
1:1,000 in blocking buffer for 30 min on ice. Cells were rinsed with
ice-cold PBS and fixed in 4% v/v paraformaldehyde for 10 min at
room temperature. Hoechst (Life Technologies) was added to wells
in PBS and cells visualised on an Olympus IX81 fluorescence micro-
scope.
Protein deglycosylation
TREM2, from conditioned media or immunoprecipitated material,
was deglycosylated using Protein Deglycosylation Mix (New England
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Biolabs) as per manufacturer’s instructions. Briefly, the sample was
mixed with glycoprotein denaturing buffer and heated to 95°C for
5 min. GlycoBuffer, NP40 and deglycosylation enzyme cocktail were
added, and the reaction was incubated for 18 h at 37°C.
siRNA
Human embryonic kidney cells stably expressing WT or H157Y vari-
ant hTREM2 and hDAP12 were plated in 24-well plates (Costar) at
50,000 cells per well; 24 h later, cells received control siRNA
(50 nM) or siRNA to ADAM10 or ADAM17 (25 nM each) or both
ADAM10 + ADAM17 siRNA (25 nM of each). The siRNA was in
smart pool format from Dharmacon, made up as stated by the
manufacturer and pre-mixed with DharmaFECT transfection reagent
prior to addition to cell cultures. Details of the siRNA used in this
study are as follows: control siRNA: ON-TARGET plus Non-targeting
Pool (D-001810-10-05); ADAM10 siRNA: ON-TARGET plus Human
ADAM10 (102) siRNA SMART pool (L-004503-00-0005); ADAM17
siRNA: ON-TARGET plus Human ADAM17 (6868) siRNA SMART
pool (L-003453-00-0005). The transfection reagent containing siRNA
was left on the cells for 72 h at which point conditioned media and
cell lysates were collected and frozen at 80°C prior to TREM2
quantification by MSD assay.
Gel-based protein visualisation: Western blotting
Cell supernatants or lysates (prepared in Cell Lysis Buffer, Cell
Signaling) were mixed with NuPAGE LDS Sample Buffer and sample
reducing agent (Life Technologies) and run on 4–12% w/v Bis–Tris
gels (Life Technologies). Gels were transferred to PVDF membrane,
which was probed with AF1828, goat anti-hTREM2 N-terminal
domain or MAB1729, rat anti-mTREM2-N-terminal domain (both
from R&D Systems, 2 lg/ml in Odyssey block or 5% w/v non-fat
milk).
Blots in the siRNA experiments were probed with polyclonal
rabbit anti-ADAM10 at 1:500 (14194S, Cell Signaling), rabbit
anti-ADAM17 at 1:500 (AB19027, Millipore) and mouse anti-b-
actin at 1:1,000 (ab3280, Abcam). Immunocomplexes were
detected using the following secondary antibodies all at 1:10,000:
rabbit anti-mouse (Thermo Scientific), rabbit, mouse or goat IgG
HRP-conjugated antibody (R&D Systems), IRDye 680RD donkey
anti-goat IgG or IRDye 800CW goat anti-rat IgG. Molecular
weight ladders used were Chameleon Duo Pre-stained Protein
Ladder (LI-COR) or MagicMarkTM XP (ThermoFisher). Blots were
either visualised on LI-COR Odyssey imaging system or using
photographic film.
Treatment with peptides and small molecule antagonists
Peptidomimetic retro-inverso peptides: C’-hvehsis-N’, C’-sisrsll-N’,
C’-hvehsisrsll-N’ & C’-fedahvehsis-N’, C’-sllegei-N’, C’-geipfpp-N’ &
C’-fpptsil-N’, were synthesised by (Cambridge Research Biochemi-
cals) and diluted in cell culture medium to concentrations of 5 mM.
The broad-spectrum metalloprotease inhibitors GM6001 (Tocris)
and batimastat (Sigma), the ADAM10 inhibitor GI254023X (Tocris),
the serine protease inhibitor PMSF (Sigma) and the MMP2/9 inhi-
bitor SB-3CT (Sigma) were diluted in cell culture medium at concen-
trations between 10 nM and 50 lM.
Immunoprecipitation of TREM2 for mass spectrometry
The cell culture medium of macrophages, microglia or HEK293
(overexpressing TREM2) was conditioned for up to 7 days, spiked
with complete protease inhibitor cocktail (Roche) and 20 mM
HEPES (Gibco) before concentrating 10-fold on molecular weight
cut-off Amicon Ultra-15 3 kDa centrifugation devices. Concentrated
medium from human cells (HEK293, macrophages) or mouse micro-
glia were incubated with goat anti-human TREM2, or rat anti-mouse
TREM2, respectively (both 10 lg/ml from R&D Systems) and
immunoprecipitated using Dynabeads Protein G (ThermoFisher).
TREM2 was eluted in 10 mM glycine, pH 1.5, and neutralised with
1.5 M Tris, pH 8.0.
TREM2 meso scale discovery immunoassay
A sandwich immunoassay quantified the concentrations of shed
TREM2 in cell culture supernatants from macrophages and
HEK293 cells over-expresssing human TREM2. Rabbit anti-TREM2
monoclonal capture antibody from Sino Biological’s ELISA was
coated at 2 lg/ml on MSD L15XA plates. Plates were washed in
0.05% v/v Tween 20 in PBS and blocked with 3% w/v BSA.
Samples and a 7-point standard curve with recombinant human
The paper explained
Problem
Neuroinflammation has been implicated in the pathogenesis of Alzhei-
mer’s disease by genomic studies. Specifically, the role of the brain’s
phagocytic cells, the microglia, has been highlighted. TREM2 is a recep-
tor protein that allows microglia to sense and potentially engulf the
amyloid plaques and cellular debris that characterise Alzheimer’s
disease. The delivery of TREM2 to the cell surface is impeded by variants
that cause neurodegenerative disease (Nasu–Hakola disease). It is less
clear whether variants linked to Alzheimer’s disease affect the levels of
TREM2 at the cell surface. The balance of delivery and proteolytic shed-
ding of TREM2 from the cell surface may have a role in the neuroin-
flammatory pathogenesis of Alzheimer’s disease.
Results
TREM2 expression on, and shedding from, human and mouse primary
myeloid cells and from human embryonic kidney cells was measured.
The sheddase activity was characterised using a range of protease
inhibitors and it was concluded that for wild-type TREM2 ADAM10, a
promiscuous metalloproteinase, was responsible, consistent with the
literature. The site of sheddase cleavage was determined (between
positions 157 and 158), initially using peptidomimetic inhibitors and
then by mass spectrometry. The disease-linked H157Y variant of
TREM2 was found to be shed more rapidly from cells; accelerated loss
might be due to the recruitment of a novel proteolytic activity.
Impact
The sheddase site identified in TREM2 lies between the folded extra-
cellular domain of TREM2 and the outer surface of the cell membrane.
From our study, the H157Y mutation at the sheddase site likely
increases risk of Alzheimer’s disease by accelerating proteolytic loss of
TREM2 from the cell surface. The sheddase site is available to poten-
tial therapeutic reagents, such as antibodies, that might protect
TREM2, favouring its retention on the microglial surface. Understand-
ing the balance of delivery and loss of TREM2 at the cell surface
might allow us to develop novel therapies to regulate neuroinflamma-
tion in Alzheimer’s disease.
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TREM2 (Sino Biological) diluted in cell culture medium were
generated and added to plates for 2 h at room temperature. Plates
were washed and each well received detection antibody (biotin-
conjugated goat anti-TREM2 from R&D, BAF1828, at 1 lg/ml in
MSD Diluent 100). Following a 1-h incubation at room tempera-
ture, plates were washed and wells treated with 1:500 strepta-
vidin–SULFO-TAG. The SULFO-TAG emits light when immobilised
on the electrode in each well and this signal is detected by a
charge-coupled device camera (MSD, www.mesoscale.com). Plates
were incubated at RT for 1 h, washed and read on the MSD
SECTOR Imager 6000. Validation of the MSD assay, showing
TREM2 specificity for both lysates and supernatants, is shown in
Fig EV4.
Briefly, plates were coated with anti-TREM2 antibody as
above. Samples for the standard curve were generated using bio-
tinylated recombinant TREM2. Experimental samples containing
biotin-TREM2 were derived from the surface-biotinylation experi-
ments. Both types of samples were detected by the addition of
streptavidin-SULFO-TAG.
Surface biotinylation and cell fractionation
Primary cultures of human macrophages were surface-biotinylated
using EZ-Link Sulfo-NHS-LC-Biotin (ThermoFisher). Following
surface biotinylation, cells were incubated at 37°C for 0–5 h.
Supernatants and cells were collected over a time course. At each
time point, cells were fractionated into membrane, organelle,
nuclear and cytosolic components using MinuteTM Plasma
Membrane Protein Isolation Kit (Invent Biotechnologies). Levels
of biotin-TREM2 in each of the samples were measured by biotin-
TREM2 MSD assay. Organelle fractions were contaminated with
plasma membrane proteins, both TREM2 and marker proteins,
and so no attempt was made to tabulate these two signals
separately.
Silver gel purification and mass spectroscopy of protein samples
Immunoprecipitated and deglycosylated TREM2 from cell cultures
was mixed with NuPAGE LDS Sample Buffer and sample reducing
agent (Life Technologies) and run on 4–12% w/v Bis–Tris gels (Life
Technologies). Following electrophoresis, gels were stained using
Pierce’s silver stain (mass spectrometry compatible) according to
manufacturer’s instructions (ThermoFisher).
The gel bands were transferred into a 96-well PCR plate cut into
1-mm2 pieces, destained, reduced (DTT) and alkylated (iodoac-
etamide) and subjected to enzymatic digestion with trypsin over-
night at 37°C. After digestion, the supernatant was loaded onto an
autosampler for automated LC-MS/MS analysis.
Mass spectrometry was performed primarily at the Cambridge
Centre for Proteomics, University of Cambridge, Cambridge, UK, and
also at the Clinical Proteomics Mass Spectrometry SciLifeLab,
Karolinska Institutet, Sweden (specifically Fig 4B and C). LC-MS/MS
experiments were performed using a Dionex Ultimate 3000 RSLC
nanoUPLC (Thermo Fisher Scientific Inc, Waltham, MA, USA) system
and a Q Exactive Orbitrap mass spectrometer (Thermo Fisher Scien-
tific Inc). Peptides were separated by reverse-phase chromatography
at a flow rate of 300 nl/min and a Thermo Scientific reverse-phase
nano Easy-spray column (Thermo Scientific PepMap C18, 2 lm
particle size, 100 A˚ pore size, 75 lm internal diameter × 50 cm
length). Peptides were loaded onto a pre-column (Thermo Scientific
PepMap 100 C18, 5 lm particle size, 100 A˚ pore size, 300 lm inter-
nal diameter × 5 mm length) from the Ultimate 3000 autosampler
with 0.1% v/v formic acid for 3 min at a flow rate of 10 ll/min. The
column valve was then switched to elute peptides from the pre-
column onto the analytical column. Solvent A was water + 0.1% v/v
formic acid, and solvent B was 80% v/v acetonitrile, 20% v/v
water + 0.1% v/v formic acid. The linear gradient applied was 2–
40% B over 30 min.
The LC eluant was sprayed into the mass spectrometer by means
of an Easy-Spray source (Thermo Fisher Scientific Inc.). All m/z
values of eluting ions were measured in an Orbitrap mass analyser,
set at a resolution of 70,000 and were scanned between m/z 380 and
1,500. Data-dependent scans (Top 20) were employed to automati-
cally isolate and generate fragment ions by higher energy collisional
dissociation (HCD, NCE:25%) in the HCD collision cell, and measure-
ment of the resulting fragment ions was performed in the Orbitrap
analyser, set at a resolution of 17,500. Singly charged ions and ions
with unassigned charge states were excluded from being selected for
MS/MS, and a dynamic exclusion window of 20 s was employed.
Post-run, the data were processed using Protein Discoverer (ver-
sion 2.1., ThermoFisher). Briefly, all MS/MS data were converted to
mgf files and the files were then submitted to the Mascot search
algorithm (Matrix Science, London, UK) and searched against a
customised UniProt human database (176,496 sequences,
61,514,126 residues) or a customised UniProt mouse database
(88,085 sequences, 37,920,032 residues). Each database contained a
common contaminant sequences (115 sequences, 38,274 residues;
http://www.thegpm.org/crap/) and modified versions of the extra-
cellular domain of TREM2 sequence in both mouse and human
versions. Briefly, a series of sequences were generated in which
amino acids were removed sequentially from the C-terminal end of
the sequences past the predicted sheddase site (H157 residue) and
up to the S147 residue. A total of 29 (human) or 25 (mouse) new
sequences were generated. Similar sequences were also generated
for the H157Y mutant version of TREM2. Variable modifications of
oxidation (M), deamidation (NQ) and carbamidomethyl were
applied. The peptide and fragment mass tolerances were set to
5 ppm and 0.1 Da, respectively. A significance threshold value of
P < 0.05 and a peptide cut-off score of 20 were also applied.
Experimental design and statistical methods
There was insufficient prior knowledge of the data to be able to
undertake formal power calculations. A minimum of three biologi-
cally independent experiments were undertaken. The variance of
the data was assessed as it was acquired and the number of required
repeats was adjusted accordingly. The range of experimental repeats
was 3–15. The data were assumed to be normally distributed and
that variance was similar between comparators. These assumptions
were not explicitly tested.
For cell biology experiments, the investigators were not blinded.
Where antibodies were employed, we used species and, where
appropriate, isotype-matched, antisera as controls for specific anti-
body binding. Parental HEK293 cells were used as controls for
hTREM2-expressing HEK293 cells. Where comparisons are made
across a Western blot, all samples were run on SDS–PAGE, blotted,
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probed and developed simultaneously. Peptidomimetics that were
adjacent to the position 157–158 cleavage site were considered
controls for the remainder. The reverse-sequence inhibitory peptido-
mimetic controlled for the effect of peptides with similar biophysical
characteristics. The mass spectroscopy investigator (MD) was
blinded. We did not randomise experiments.
Expanded View for this article is available online.
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